Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price

Bristol Myers Squibb (BMY) is flagged as undervalued at a 9.8x forward P/E with a 3.7% yield. The growth portfolio now contributes ~60% of revenue and supports ~5% YoY total revenue growth as legacy declines are offset. Management raised full-year adjusted EPS guidance, supported by strong Eliquis growth and a pipeline of 10+ potential new medicines.

Analysis

The key setup is not the near-term EPS beat; it’s the market’s willingness to stop pricing BMY as a melting-ice-cube cash cow. A sub-10x forward multiple with a mid-single-digit growth profile and an above-market yield usually only persists when investors believe the replacement engine fails — so the current setup gives room for a 1-2 turn re-rating if the next two quarters confirm that the growth mix is broadening rather than just being propped up by one franchise.

The second-order effect is capital allocation: if operating cash flow remains stable, BMY can keep defending the dividend while still funding BD or buybacks, which lowers the probability of a forced balance-sheet pivot later. That matters for the whole large-cap pharma cohort because it raises the bar for peers like PFE and SNY that are still battling credibility on post-cliff earnings durability; relative performance can shift toward the names with visible cash conversion and away from those leaning mostly on yield.

The contrarian risk is that investors may be extrapolating a guide raise that is still dependent on a narrow set of assets, while the real test sits 6-18 months out when newer products need to offset legacy decay on a cleaner base. The stock can rerate now on sentiment, but it will likely give that back fast if Eliquis growth decelerates, a late-stage readout slips, or management has to revise 2025 EPS lower. What would falsify the bullish case is not a weak day of trading; it is any indication that the growth portfolio fails to sustain high-single-digit revenue contribution or that pipeline conversion stalls before the next patent-pressure step-down.

Key Decisions for Investors

• Long BMY common on weakness over the next 1-2 weeks: base case is a modest multiple expansion toward 11x forward P/E if the market believes the growth mix is durable; downside is limited by the yield, but the thesis breaks if the next earnings update does not preserve the raised EPS range.
• Pair trade: long BMY / short PFE for a 3-6 month relative-value position. BMY has the cleaner near-term evidence of mix improvement; PFE still carries a heavier credibility discount around post-cliff earnings power. Exit the pair if BMY re-rates to parity on valuation or if PFE delivers a guide reset that narrows the gap.
• Use BMY as a defensive pharma overweight versus XLV if rates stay elevated or risk appetite fades. The stock should benefit from income-seeking flows even if absolute upside is capped; consider trimming if it moves to a valuation that implies no patent-cliff risk.
• Set a watch item on Eliquis growth and 2025 EPS revisions as the true falsifiers. If either slows materially, expect the stock to compress back below 9x forward earnings quickly, making the current rerating thesis invalid.
• For broader exposure to the thesis, consider a relative long in large-cap pharma over biotech (e.g., BMY vs XBI) only if the goal is income-plus-defensiveness; otherwise the signal is too idiosyncratic to justify a sector trade.